人肺腺癌肿瘤细胞免疫表型CDl33、CD34、CD44的实验研究  

Experimental research of immunophenotype CD133, CD34, CD44 in human lung adenocarcinoma c

作　　者：谭思创[1] 王若星[1] 谭斯品[2] 胡文[1] 马宇超[1] 喻风雷[1] 

机构地区：[1]中南大学湘雅二医院心胸外科,长沙410011 [2]中南大学基础医学院病理生理学系

出　　处：《中国医师杂志》2011年第5期592-595,共4页Journal of Chinese Physician

基　　金：教育部博士点基金资助（20070533066）

摘　　要：目的拟验证CDl33、CD34、CD44作为人肺腺癌肿瘤干细胞表面标记物的合理性。方法采集新鲜肺腺癌组织标本，利用两种体外培养方法扩增出贴壁细胞和悬浮细胞球两种肿瘤细胞，采用免疫荧光检测比较CDl33、CD34和CD44在两种培养细胞中表达的差异。结果悬浮球肿瘤细胞培养较贴壁肿瘤细胞生长速度慢、维持时间长且成功率高（72．5％VS47．5％，P〈0．05）。CDl33、CD34和CD44在悬浮细胞球中表达率和表达量明显高于贴壁肿瘤细胞（68．97％，82．76％，93．10％VS5．26％，15．79％，5．26％，P〈0．01）。结论CDl33、CD34和CD44可能作为分离人肺腺癌肿瘤干细胞的表面蛋白表标记组合。Objective To validate the possibility of CD133 CD34 CD44 be served as biomarkers in cancer stem cell of human lung adenocarcinoma. Methods Two kinds of culturing methods were performed to generate adhesive tumor cells and floating aggregates, and the differences of expression of CD133 CD34 CD44 between 2 kinds of cultured cells were observed by immunofluorescence. Results Floating aggregates grew more slowly, kept activity for longer period than adhesive cells （72. 5% vs 47.5% , P 〈 0. 05 ）. Floating aggregates expressed higher level of CD133, CD34 and CD44 than adhesive cells （68.97%, 82.76%, 93.10% vs 5.26%, 15.79%, 5.26%, P 〈 0. 01 ）. Conclusions The combination of CD133, CD34 and CD44 probably can be used as surface markers of cancer stem cells for human lung adenocarcinoma.

关 键 词：肺肿瘤/免疫学 肿瘤干细胞测定 抗原 CD34/代谢 抗原 CD44/代谢 抗 原 CD/代谢 

分 类 号：R734.2[医药卫生—肿瘤]